Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was observed in lesions not directly injected with KB113, consistent with
Share
Why It Matters
Krystal Biotech's medicine KB113 shrank tumors in Gorlin patients. This shows the drug might work in ways doctors didn't expect.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.